找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Cancer Therapeutic Targets; John L. Marshall Living reference work 20200th edition Anti-angiogenic Targets.HER2/EGFR Targets.Nuclear Rece

[复制链接]
查看: 32416|回复: 64
发表于 2025-3-21 19:57:02 | 显示全部楼层 |阅读模式
书目名称Cancer Therapeutic Targets
编辑John L. Marshall
视频video
概述This reference work would be the first of its kind.Organized into major sections based on distinct aspects of cancer cell biology, each sub-section (galaxy) would provide comprehensive but brief 4-5 p
图书封面Titlebook: Cancer Therapeutic Targets;  John L. Marshall Living reference work 20200th edition  Anti-angiogenic Targets.HER2/EGFR Targets.Nuclear Rece
描述.In the past decade, we have experienced an explosion of new information about cancer therapeutic targets. Many of the targets have been validated by the discovery and approval of new medicines which have been approved for the treatment of cancer. On the heels of these successes, innumerable new targets and new potential therapeutics are being developed by many different groups including government agencies, pharmaceutical companies, biotechnology companies, academic institutions, and individual investigators. Understanding the expanding "universe" of cancer therapies is therefore becoming impossible and no single source exists which serves as a reference for the involved parties. Further, the interested parties have vastly different areas of expertise, from focused laboratory based science, to clinical research, to corporate and regulatory oversight...The text would be updated every two years, more often depending on pace of change, interest and sales. While useful online, this reference book would likely be kept in hard copy as well..
出版日期Living reference work 20200th edition
关键词Anti-angiogenic Targets; HER2/EGFR Targets; Nuclear Receptors; Hormone Receptors; Heme surface markers
doihttps://doi.org/10.1007/978-1-4614-6613-0
isbn_ebook978-1-4614-6613-0
The information of publication is updating

书目名称Cancer Therapeutic Targets影响因子(影响力)




书目名称Cancer Therapeutic Targets影响因子(影响力)学科排名




书目名称Cancer Therapeutic Targets网络公开度




书目名称Cancer Therapeutic Targets网络公开度学科排名




书目名称Cancer Therapeutic Targets被引频次




书目名称Cancer Therapeutic Targets被引频次学科排名




书目名称Cancer Therapeutic Targets年度引用




书目名称Cancer Therapeutic Targets年度引用学科排名




书目名称Cancer Therapeutic Targets读者反馈




书目名称Cancer Therapeutic Targets读者反馈学科排名




单选投票, 共有 1 人参与投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 22:36:34 | 显示全部楼层
Anti-Apoptotic Bcl-2,hway. Approximately 25 members of the BCL-2 family have been grouped into three categories based on structure and function: (1) anti- apoptotic, (2) pro-apoptotic, and (3) BH3 only proteins. This chapter will focus on a family of five anti-apoptotic proteins: (1) BCL-2, (2) BCL-xL, (3) BCL-w, (4) MC
发表于 2025-3-22 03:24:05 | 显示全部楼层
发表于 2025-3-22 05:50:43 | 显示全部楼层
发表于 2025-3-22 08:46:03 | 显示全部楼层
Anti-Idiotype Antibodies,ed to as the “idiotype” (Id), is composed of the unique antigenic determinants in the variable regions of the clonal Ig heavy and light chains expressed by the tumor cells (Timmerman and Levy 2000). This protein target has the unusual nature of being unique in every B-cell cancer (Fig. 1). The human
发表于 2025-3-22 16:47:42 | 显示全部楼层
发表于 2025-3-22 18:43:26 | 显示全部楼层
APC,s a critical suppressor of cancer initiation. Individuals who inherit inactivating mutations in one allele of the . gene exhibit familial adenomatous polyposis (FAP) coli, an autosomal dominant syndrome characterized by the formation of a variety of benign lesions, particularly numerous adenomatous
发表于 2025-3-22 23:20:50 | 显示全部楼层
发表于 2025-3-23 02:00:46 | 显示全部楼层
发表于 2025-3-23 05:51:23 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-6-24 04:49
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表